Abraham Chesed
CIK: 0002094374
Abraham Chesed's purchase track record
Abraham Chesed has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/23/2025 | TTRX | $66K | -4.4% | -32.3% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TTRX | ▲ Buy | Open Market | 14,286 | $66K | 10/23/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Lucid Capital initiates coverage on TTRX with $24 target
Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.
Lucid Capital initiates coverage on TTRX with $24 target. Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.